Prof. Jian Ding is a renowned Chinese cancer pharmacologist and Academician of the Chinese Academy of Engineering, and he’s made extraordinary contributions to research and development of new drugs. He is currently a researcher at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and was Director of the Shanghai Institute of Materia Medica, CAS (2004-2013). Prof. Ding serves as the editor-in-chief of Acta Pharmacologica Sinica and editorial board member of several international academic journals such as Eur J Pharmacol, J Ethnopharmacol and Mol Pharmacol. Focusing on biomarkers and drug resistance mechanisms of anti-tumor drugs, I am the co-inventor of more than ten innovative drug candidates, and all of which are currently at clinical trials with one of them has been conditionally approved, two of them have already filed for listing and 5 of them running additional clinical tests in U.S, Japan & Australia. More than 340 papers have been published in journals including Cell、Cancer Cell、Molecular Cancer、Cell Res etc. Over 150 patents have been authorized. Multiple awards have been bestowed to Prof. Ding to acknowledge his tremendous contribution to the area of cancer treatment, including but not limited to, 2 Second degree of National Natural Science Award, the 2nd National Innovation Competition Medal, the Outstanding Science and Technology Achievement Award of the Chinese Academy of Sciences, etc